A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study

Celestia S. Higano, John J. Crowley, Robert V. Veith, Robert B Livingston

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Twenty-two eligible patients with previously untreated extensive small cell lung cancer received intravenous vinorelbine 30 mg/M2 each week until progression. Response was assessed every 4 weeks by chest x-ray or every 8 weeks by CT scan. All responses had to be 'confirmed' at all involved sites at least 4 weeks later. Fourteen patients were male and 8 were female with a median age of 64.5 years (range 38-76). Fifteen patients were Caucasian and 7 were African-American. One patient had a 'confirmed' partial response, 3 had unconfirmed responses, 13 had stable or progressive disease, and 5 did not have adequate data. The median progression-free survival was 3 months with a median overall survival of 8 months. Thirteen patients experienced 22 episodes of grade 3 toxicity, more than half due to leukopenia and neutropenia, and 1 due to paresthesias. Of 4 episodes of grade 4 toxicity, 1 was due to leukopenia and 3 were due to hyponatremia which was not due to vinorelbine. Significant thrombocytopenia did not occur. The activity of single agent vinorelbine in untreated small cell lung cancer was disappointing when analyzed by Southwest Oncology Group (SWOG) criteria. The median survival in this trial was similar to that found in other SWOG trials using cisplatin based front line therapy and thus confirms previously reported findings that initial treatment with a phase II agent followed by a cisplatin based regimen at progression does not adversely affect overall survival in this population of patients.

Original languageEnglish (US)
Pages (from-to)153-156
Number of pages4
JournalInvestigational New Drugs
Volume15
Issue number2
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Leukopenia
Cisplatin
Survival
Hyponatremia
Paresthesia
Neutropenia
Thrombocytopenia
African Americans
Disease-Free Survival
vinorelbine
Thorax
X-Rays
Therapeutics
Population

Keywords

  • Navelbine
  • Small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study. / Higano, Celestia S.; Crowley, John J.; Veith, Robert V.; Livingston, Robert B.

In: Investigational New Drugs, Vol. 15, No. 2, 1997, p. 153-156.

Research output: Contribution to journalArticle

@article{cfabeb92492a47daa1dc7288965bf8a3,
title = "A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study",
abstract = "Twenty-two eligible patients with previously untreated extensive small cell lung cancer received intravenous vinorelbine 30 mg/M2 each week until progression. Response was assessed every 4 weeks by chest x-ray or every 8 weeks by CT scan. All responses had to be 'confirmed' at all involved sites at least 4 weeks later. Fourteen patients were male and 8 were female with a median age of 64.5 years (range 38-76). Fifteen patients were Caucasian and 7 were African-American. One patient had a 'confirmed' partial response, 3 had unconfirmed responses, 13 had stable or progressive disease, and 5 did not have adequate data. The median progression-free survival was 3 months with a median overall survival of 8 months. Thirteen patients experienced 22 episodes of grade 3 toxicity, more than half due to leukopenia and neutropenia, and 1 due to paresthesias. Of 4 episodes of grade 4 toxicity, 1 was due to leukopenia and 3 were due to hyponatremia which was not due to vinorelbine. Significant thrombocytopenia did not occur. The activity of single agent vinorelbine in untreated small cell lung cancer was disappointing when analyzed by Southwest Oncology Group (SWOG) criteria. The median survival in this trial was similar to that found in other SWOG trials using cisplatin based front line therapy and thus confirms previously reported findings that initial treatment with a phase II agent followed by a cisplatin based regimen at progression does not adversely affect overall survival in this population of patients.",
keywords = "Navelbine, Small cell lung cancer, Vinorelbine",
author = "Higano, {Celestia S.} and Crowley, {John J.} and Veith, {Robert V.} and Livingston, {Robert B}",
year = "1997",
doi = "10.1023/A:1005869008452",
language = "English (US)",
volume = "15",
pages = "153--156",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study

AU - Higano, Celestia S.

AU - Crowley, John J.

AU - Veith, Robert V.

AU - Livingston, Robert B

PY - 1997

Y1 - 1997

N2 - Twenty-two eligible patients with previously untreated extensive small cell lung cancer received intravenous vinorelbine 30 mg/M2 each week until progression. Response was assessed every 4 weeks by chest x-ray or every 8 weeks by CT scan. All responses had to be 'confirmed' at all involved sites at least 4 weeks later. Fourteen patients were male and 8 were female with a median age of 64.5 years (range 38-76). Fifteen patients were Caucasian and 7 were African-American. One patient had a 'confirmed' partial response, 3 had unconfirmed responses, 13 had stable or progressive disease, and 5 did not have adequate data. The median progression-free survival was 3 months with a median overall survival of 8 months. Thirteen patients experienced 22 episodes of grade 3 toxicity, more than half due to leukopenia and neutropenia, and 1 due to paresthesias. Of 4 episodes of grade 4 toxicity, 1 was due to leukopenia and 3 were due to hyponatremia which was not due to vinorelbine. Significant thrombocytopenia did not occur. The activity of single agent vinorelbine in untreated small cell lung cancer was disappointing when analyzed by Southwest Oncology Group (SWOG) criteria. The median survival in this trial was similar to that found in other SWOG trials using cisplatin based front line therapy and thus confirms previously reported findings that initial treatment with a phase II agent followed by a cisplatin based regimen at progression does not adversely affect overall survival in this population of patients.

AB - Twenty-two eligible patients with previously untreated extensive small cell lung cancer received intravenous vinorelbine 30 mg/M2 each week until progression. Response was assessed every 4 weeks by chest x-ray or every 8 weeks by CT scan. All responses had to be 'confirmed' at all involved sites at least 4 weeks later. Fourteen patients were male and 8 were female with a median age of 64.5 years (range 38-76). Fifteen patients were Caucasian and 7 were African-American. One patient had a 'confirmed' partial response, 3 had unconfirmed responses, 13 had stable or progressive disease, and 5 did not have adequate data. The median progression-free survival was 3 months with a median overall survival of 8 months. Thirteen patients experienced 22 episodes of grade 3 toxicity, more than half due to leukopenia and neutropenia, and 1 due to paresthesias. Of 4 episodes of grade 4 toxicity, 1 was due to leukopenia and 3 were due to hyponatremia which was not due to vinorelbine. Significant thrombocytopenia did not occur. The activity of single agent vinorelbine in untreated small cell lung cancer was disappointing when analyzed by Southwest Oncology Group (SWOG) criteria. The median survival in this trial was similar to that found in other SWOG trials using cisplatin based front line therapy and thus confirms previously reported findings that initial treatment with a phase II agent followed by a cisplatin based regimen at progression does not adversely affect overall survival in this population of patients.

KW - Navelbine

KW - Small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0030949066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030949066&partnerID=8YFLogxK

U2 - 10.1023/A:1005869008452

DO - 10.1023/A:1005869008452

M3 - Article

C2 - 9220295

AN - SCOPUS:0030949066

VL - 15

SP - 153

EP - 156

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -